The Peter Attia Drive 2024年07月26日
#102 - Michael Osterholm, Ph.D.: COVID-19—Lessons learned, challenges ahead, and reasons for optimism and concern
index_new5.html
../../../zaker_core/zaker_tpl_static/wap/tpl_guoji1.html

 

迈克尔·奥斯特霍姆,明尼苏达大学传染病研究与政策中心主任,在本期节目中概述了新冠疫情至今的情况,分享了关于疾病传播方式的见解,并对未来可能发生的事情表达了他的乐观与悲观看法。他讨论了真实的病例死亡率,为何世界各地存在差异,以及哪些基础疾病如肥胖会影响重症和死亡风险。此外,还探讨了疫苗前景、治疗药物/抗病毒药物的重用,以及他对于药品、疫苗、N95口罩和检测套件供应链限制的担忧。

🌍 迈克尔回顾了新冠疫情的简短历史,并对未来可能发生的情况进行了展望,指出我们需要关注的重要领域。

🩺 他探讨了真正的病例死亡率,分析了不同国家之间的差异,以及年龄、基础疾病和肥胖对重症和死亡的影响。

🛡️ 对于保护医护工作者,迈克尔提出了自己的看法和建议,强调了保护医护人员的重要性。

🔬 他表达了对检测能力的担忧,包括试剂短缺和供应链问题,这些都是当前抗疫工作的关键挑战。

💉 迈克尔讨论了疫苗和抗病毒药物的前景、时间表以及面临的挑战,为未来的治疗提供了洞见。

In this episode, Michael Osterholm, Director of the Center for Infectious Disease Research and Policy at the University of Minnesota and author of Deadliest Enemy: Our War Against Killer Germs, provides an overview on the COVID-19 pandemic in regards to what has happened to date, what we’ve learned about how the disease spreads, and his optimism and pessimism about what potentially lies ahead. Michael gives his take on the true case fatality rate, why it differs around the world, and which underlying conditions, such as obesity, impact risk of severe illness and death. We also discuss the outlook regarding vaccines, repurposed drugs/antivirals for treatment, and Michael’s growing concern about supply chain limitations with respect to drugs, vaccines, n95 masks, and testing kits. We discuss:

Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/michaelosterholm Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.

Fish AI Reader

Fish AI Reader

AI辅助创作,多种专业模板,深度分析,高质量内容生成。从观点提取到深度思考,FishAI为您提供全方位的创作支持。新版本引入自定义参数,让您的创作更加个性化和精准。

FishAI

FishAI

鱼阅,AI 时代的下一个智能信息助手,助你摆脱信息焦虑

联系邮箱 441953276@qq.com

相关标签

新冠疫情 病例死亡率 疫苗研发 供应链挑战
相关文章